Butalin (Terbutaline) is a type of medication known as a bronchodilator, which is utilized for managing respiratory symptoms related to certain lung conditions. Terbutaline tablets are used to help manage symptoms such as wheezing, shortness of breath, and chest tightness.

---

Key Therapeutic Areas

The medication is typically used for conditions involving bronchospasm. The common therapeutic areas include asthma and the symptoms associated with chronic obstructive pulmonary disease (COPD), such as chronic bronchitis and emphysema. The primary benefit is to support breathing during difficult episodes. This medication is recognized for its role in supporting easier breathing in these chronic conditions.

Quick Fact: Relief for Wheezing Butalin helps to manage wheezing associated with these conditions.

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility Map: Who Can and Cannot Use Butalin (Terbutaline) — Official Regulatory Information

Eligibility Scope	Detail (Per Regulatory Labeling)
Populations for whom use is allowed	Patients 12 years of age and older who require prevention or reversal of bronchospasm.
Populations for whom use is not recommended	Children younger than 12 years of age (oral and injectable forms for bronchospasm are generally not recommended or established).
Populations for whom use is contraindicated	Patients with known hypersensitivity to Terbutaline or sympathomimetic amines. Pregnant women for prolonged tocolysis (beyond 48–72 hours) or any treatment of preterm labor using the oral tablet formulation.

Age-related eligibility rules: The medicine is officially indicated for patients starting at 12 years of age. Older adults (65 years and older) should use the drug with caution due to the higher likelihood of age-related changes in cardiac or renal function.

Condition-specific eligibility rules: Use is restricted and requires caution in patients with pre-existing conditions that may be aggravated by sympathomimetic agents, including cardiovascular disorders (such as ischemic heart disease, hypertension, and arrhythmias), diabetes mellitus, hyperthyroidism, and convulsive disorders. Caution is also required in patients with renal impairment due to the drug's elimination route.

Pregnancy and lactation eligibility status: For the labeled bronchospasm indication, the drug is used only when the potential benefit justifies the risk. The drug is excreted in human milk, and the decision on its use must weigh the mother's need for the drug against any risk to the nursing infant.

---

Connection to the overall eligibility profile Official regulatory documents define eligibility by establishing absolute contraindications based on hypersensitivity and explicitly prohibiting unapproved obstetric uses (tocolysis). Use is otherwise permitted for the approved age range, provided that the patient is monitored carefully for risk associated with pre-existing cardiovascular or metabolic conditions.

The interaction profile of Butalin (Terbutaline) is defined by pharmacodynamic effects on the cardiovascular system and potassium levels, as documented in regulatory labeling.

Interaction Classifications (High-Level)

Classification	Interacting Agents or Context
Contraindicated Combination	Oral tablets and injection use for acute or maintenance tocolysis (preterm labor treatment) is contraindicated by the FDA.
Combination Not Recommended	Other Sympathomimetic Agents due to the potential for deleterious combined effects on the cardiovascular system.
Combination Requiring Caution	Beta-Adrenergic Receptor Blocking Agents (Beta-Blockers) may block the pulmonary effect of terbutaline and produce severe bronchospasm.

Official Interaction Statements

• Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants (TCAs) may potentiate the vascular effects of terbutaline. Administration requires extreme caution if taken concurrently or within two weeks of discontinuation of such agents.
• Non-Potassium Sparing Diuretics (such as thiazide or loop diuretics) can worsen the hypokalemia and ECG changes that may result from terbutaline therapy.
• Other agents, including Xanthine Derivatives and Steroids, are documented to potentiate the hypokalemic effect associated with beta-agonist use.

The regulatory documents primarily emphasize the risks of antagonistic airway effects and additive cardiovascular or hypokalemic outcomes when terbutaline is co-administered with other sympathomimetic, antidepressant, or potassium-lowering medicines.

Selective Activation of Airway beta2-Receptors

The mechanism of Terbutaline involves selective agonism at the beta2-adrenergic receptors (beta2-ARs) found on the bronchial smooth muscle. This targeted interaction initiates the entire cascade and directly engages the cellular machinery responsible for smooth muscle tone regulation.

The Intracellular Relaxation Cascade (cAMP Pathway)

Binding to the beta2-AR activates the Gs protein and subsequently the Adenylate Cyclase enzyme, leading to a surge in intracellular cAMP. This molecular increase activates Protein Kinase A (PKA), which functions to inactivate the enzyme MLCK and reduce calcium, resulting in the relaxation of the smooth muscle. This physiological change leads to an increase in the airway lumen diameter, which mechanically alters airflow dynamics.

Secondary Physiological Modulation and Limitations

The same receptor activation pathway inhibits mast cell degranulation, thereby reducing the release of inflammatory mediators, and increases ciliary beat frequency, resulting in enhanced mucus transport. However, this specific mechanism is susceptible to tachyphylaxis (receptor desensitization) due to prolonged or high-level receptor exposure, and the degree of induced relaxation is physiologically constrained by any existing, severe, non-reversible structural remodeling in the airway wall.

Terbutaline is administered via several approved routes depending on the clinical requirement, including oral (tablets), inhalation (powder or nebulizer solution), and subcutaneous (SC) injection for acute management. The choice of form dictates the usage pattern.

Oral Dosing and Frequency

Tablets are used on a scheduled basis, typically administered three times a day (TID) at intervals of approximately six hours during waking hours. The usual adult maintenance dose is 5 mg TID, though the starting dose may be 2.5 mg TID. There is a strict maximum daily dose of 15 mg per 24 hours. If a dose is missed, procedural instructions specify that the dose should not be doubled.

Acute Administration and Technique

The SC injection is restricted to 0.25 mg per dose, repeatable once after 15 to 30 minutes, with a maximum of 0.5 mg over a four-hour period. For inhalation, use is as-needed, and proper technique requires a forceful, deep inhalation through the device, followed by rinsing the mouth and spitting out the rinse water.

Population Adjustments

Specific use parameters exist for certain groups. The oral tablet and SC injection forms are not recommended for use in children younger than 12 years. For adults with impaired kidney function (GFR < 50 mL/min), the parenteral dose (SC or IV) is to be reduced by 50%.

Butalin (Terbutaline): Recent Clinical Evidence

---

Therapeutic Role in Bronchospasm

Terbutaline is a short-acting beta2-adrenergic agonist (SABA) studied for the prevention and reversal of bronchospasm associated with asthma and Chronic Obstructive Pulmonary Disease (COPD) in patients aged 12 and older. Clinical studies have historically shown that terbutaline can increase pulmonary function, as measured by a sustained improvement of 15% or more in Forced Expiratory Volume in 1 second (FEV1).

Comparative and Contemporary Research

Recent research has compared injectable terbutaline to other rescue bronchodilators for the out-of-hospital management of acute asthma or COPD exacerbations. Findings suggest that while both treatments resulted in substantial improvements in overall respiratory symptoms, other nebulized agents may be associated with greater patient-rated improvements in dyspnea (shortness of breath).

In the context of standard guidelines, inhaled bronchodilators remain central to the management of COPD. Current guidelines emphasize that short-acting beta2-agonists, including terbutaline, should generally not be used as monotherapy for asthma. Overuse of SABA has been associated with an increased risk of severe asthma exacerbations, highlighting the importance of using these agents alongside appropriate anti-inflammatory maintenance therapy.

Safety in Acute Settings

In studies involving continuous intravenous terbutaline for severe pediatric asthma, the infusion was generally observed to be well tolerated. While hemodynamic and metabolic disturbances (e.g., changes in heart rate, blood pressure, and transient decreases in serum potassium levels) occurred, these effects were typically clinically manageable and resolved shortly after the infusion was discontinued.

Key Studies & References

1. Terbutaline Sulfate Injection Label - Indications, Warnings, and Use
2. Short-acting beta 2 agonists (SABA) (salbutamol and terbutaline): reminder of the risks from overuse in asthma and to be aware of changes in the SABA prescribing guidelines - GOV.UK

Common questions about Butalin (Terbutaline) (FAQ)

Q: How quickly does Butalin start working after taking it?

According to official documentation, the time it takes for Butalin to start working depends on the formulation. The oral tablet typically begins to work within approximately 30 minutes. The subcutaneous injection form, which is used for acute management, is described as having an onset of action within about 15 minutes.

Q: How long does the effect of Butalin usually last?

For the oral tablet formulation, official product information indicates that the effects are generally described as lasting up to six hours or longer. The prescribing information is designed to align with this duration.

Q: Is it normal to feel shaky or nervous after taking Butalin?

Official labeling lists tremor (shakiness) and nervousness as very common adverse reactions. These reactions are associated with the stimulating properties of the medicine as a sympathomimetic amine. Regulatory documents describe these effects as generally transient (temporary) in nature, often diminishing with continued use.

Q: What is the difference between Butalin and albuterol (salbutamol)?

Official sources categorize both Butalin (Terbutaline) and albuterol (salbutamol) as short-acting beta agonists (SABAs), meaning they work quickly to relax airway muscles. Differences noted in regulatory documents relate to the available dosage forms (Butalin being available as an oral tablet, albuterol primarily as an inhaler) and the authorized age indications for use.

Q: Can Butalin be used by people with high blood pressure?

Official information states that Butalin is a sympathomimetic amine, which can affect the circulatory system. Because of this, regulatory documents recommend that the drug should be used with caution in patients who have hypertension (high blood pressure).

Q: What are the signs that Butalin is not working anymore?

Regulatory documents state that worsening asthma is indicated if a previously effective dosage regimen fails to provide the usual relief or if symptoms require the medicine to be used more frequently than usual. If this change is observed, official guidance indicates the situation warrants communication with a healthcare professional.

Q: Can Butalin be taken on an empty stomach?

Official regulatory documents typically focus on the timing of the oral tablet in relation to other doses. Regulatory documents prioritize the timing of the dose (e.g., at set intervals) over instructions concerning food intake.

Q: Are there certain foods or drinks that should be avoided with Butalin?

Official drug interaction lists focus on potential issues with other medications, such as sympathomimetic agents, antidepressants, and diuretics. No specific foods or common non-prescription drinks are listed as interactions that must be avoided in authoritative labeling.

Q: What happens if a dose of Butalin is missed?

Patient instructions generally address the timing of a missed dose by setting a rule about how close the missed dose is to the next scheduled dose. These instructions also clearly state that a dose should not be doubled to make up for the missed one.

Q: Does Butalin help with coughing or only with wheezing?

Butalin is officially indicated for the prevention and reversal of bronchospasm, which is the tightening of muscles around the airways. The action of relaxing these muscles is intended to widen the breathing tubes, which is used in the management of symptoms such as wheezing and shortness of breath.

Q: Does Butalin interact with common pain relievers like Tylenol (acetaminophen)?

Official drug interaction lists specifically warn against using the medicine with other medications that stimulate the cardiovascular system (sympathomimetic agents). Acetaminophen (a common pain reliever) is not explicitly listed as an interaction in official regulatory documents.

Q: Can Butalin cause trouble sleeping or insomnia?

Yes, official safety data lists insomnia (trouble sleeping) as a reported adverse reaction in clinical studies. This is consistent with the nature of the drug as a sympathomimetic amine.

Q: Is it possible to be allergic to Butalin?

Yes, official regulatory labeling includes hypersensitivity to terbutaline sulfate or to related sympathomimetic amines as a contraindication for use. This indicates that the medicine should not be used if a patient has a known allergy to the active ingredient.

Q: Can Butalin interact with herbal supplements?

While specific herbal supplements are not detailed in official regulatory documents, patient instructions generally advise informing a healthcare professional about all products being used, including natural or herbal products.

Q: Can I drive or operate machinery after taking Butalin?

Official labeling lists side effects such as dizziness and somnolence (sleepiness) as potential adverse reactions. Official guidance suggests individuals evaluate their response to the drug before engaging in activities that require full attention, due to the potential for these effects.

Q: Is Butalin ever prescribed for conditions other than breathing problems?

The only approved use for Butalin is to prevent and relieve bronchospasm. However, official labeling includes a Boxed Warning that explicitly restricts its use for tocolysis (treating preterm labor), acknowledging that it has an unapproved historical use for that purpose.

Q: What is the recommended interval between doses of Butalin?

For the oral tablet, official documents recommend administration at approximately six-hour intervals during waking hours. For the subcutaneous injection used in acute settings, the dose may be repeated once after 15 to 30 minutes.

Q: Does Butalin make you feel dizzy or lightheaded?

Official safety information lists dizziness as a potential adverse reaction. As with any medication that affects the nervous system, individuals are encouraged to be aware of how they respond after taking the medicine.

Q: Can Butalin cause muscle cramps or weakness?

Yes, official labeling lists asthenia (general weakness) as a Common adverse reaction. Muscle cramps are also included in the category of less frequent adverse effects noted in regulatory documentation.

Q: How long after stopping Butalin do the side effects typically go away?

Regulatory documents state that most adverse reactions are transient in nature and generally resolve shortly after the drug is discontinued. However, some effects, such as tachycardia (rapid heart rate), may persist for a relatively longer time.

Q: Is Butalin related to adrenaline?

Butalin belongs to a class of medicines called sympathomimetic amines. Official labeling notes that the drug is contraindicated in individuals with a known hypersensitivity to the class of compounds, which includes both Butalin and natural substances like adrenaline.

Q: What are the reported effects of an accidental overdosage of Butalin?

Official labeling describes the expected effects of overdosage as those resulting from excessive stimulation of the body’s sympathetic system. These effects may include seizures, severe nervousness, headache, tremor, palpitations, and cardiac arrhythmia.

Q: Does the packaging for Butalin contain a specific warning label?

The oral tablet formulation of the active ingredient contains an FDA-mandated Boxed Warning. This warning specifically states that the drug should not be used for acute or maintenance tocolysis (treating preterm labor).

Q: What do official sources say about Butalin use and heart conditions?

Official labeling notes potential serious adverse reactions, including myocardial ischemia (heart attack) and arrhythmias (irregular heart rhythms). It states that the drug should be used with caution in patients with pre-existing cardiovascular disorders.

Q: Is it true that Butalin was once used to prevent premature labor?

Yes, official documents, by carrying a Boxed Warning that explicitly states the oral tablets are not approved for acute or maintenance tocolysis, implicitly address the historical use of the drug for this purpose.

Q: Can Butalin be used if I have thyroid problems?

Official information states that the medicine should be used with caution in patients with hyperthyroidism (overactive thyroid). This caution is related to the stimulating properties of the drug, which may affect an existing hyperthyroid condition.

Q: Does the effectiveness of Butalin decrease over time (tolerance)?

The drug's mechanism is noted to be susceptible to tachyphylaxis, which is a scientific term for a rapid decrease in response to a drug after repeated administration. If the medicine appears less effective, this change warrants communication with a healthcare professional.

Q: Why does my mouth feel dry after using Butalin?

Official safety data lists dry mouth as an adverse reaction that has been reported in a small percentage of patients during clinical studies.

Terbutaline storage and disposal must strictly follow the official instructions for each formulation.

Storage Scope	Official Regulatory Requirement
Temperature & Protection	Store at room temperature (20 C to 25 C), protected away from heat, moisture, and direct light (tablets) or heat and light (injection). Do not freeze
In-Use Stability	An open vial of the injection solution must be used right away; nebulization single-dose units must be used within 24 hours of opening.
Container Rule	Tablets must be kept in a closed container. Injection vials should be retained in the original carton prior to use.
Child Safety	Keep out of the reach of children. The sharps container used for disposing of injection needles must also be kept away from children and pets.
Disposal Instructions	Ask a healthcare professional how to dispose of unused or expired medicine. Used injection needles must be placed in a hard, closed container for sharps disposal.

These mandated rules define how the product must be stored, protected, handled, and discarded to maintain its quality and ensure safety.